NTS N° ID • MINSA/DGSP V.01 NORMA TÉCNICA DE SALUD PARA LA ATENCIÓN INTEGRAL DE LAS PERSONAS AFECTADAS POR TUBERCULOSIS
IX.
BIBLIOGRAFÍA 1. Ait-Khaled N, Alarcon E, Armegon R, Bissell K, Boillot F, Caminero JA, y col. Manejo de la Tubercdulosis. Una Guía Esencial de Buenas Prácticas. París, Francia: Unión Internacional contra la Tuberculosis y Enfermedades Respiratorias, 2010. 2. Asencios L, Galarza M, Quispe N, Vásquez L, et al. Molecular test Genotype® MTBDRpIus, an alternative to rapid detection of multidrug resistance tuberculosis. Rev Peru MedExp Salud Pública. 2012;29:92-8 3. Asencios L, Quispe N, Mendoza-Ticona A. et al. Vigilancia nacional de la resistencia a medicamentos antituberculosos, Perú 2005-2006. Rev Peru MedExpSaludPublica. 2009; 26(3): 278-87. 4. Atkinson J, Chartier Y, Pessoa-Silva, et al. Ventilación natural para el control de las infecciones en entornos de atención de la salud. Organización Panamericana de la Salud; 2010. 5. Barnard M, Warren R, Van Pittius NG, van Helden P, Bosman M, Streicher E, et al. GenoTypeMTBDRsl Line Probe Assay Shortens Time to Diagnosis of XDR-TB in a Highthroughput Diagnostic Laboratory. Am. J. Respir. Crit. Care Med. 2012; 15;186:1298-305 6. Bartacek A, Shutt D, Panosch B, Borek M. Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis. Int J TubercLung Dis. 2009; 13:760-6. 7. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N. Engl. J. Med. 2010; 363: 1005-15. 8. Bonilla CA, Crossa A, Jave HO, Mitnick CD, Jamanca RB, et al. Management of Extensively Drug-Resistant Tuberculosis in Peru: Cure Is Possible. PLoS ONE 2008 3(8): e2957. doi:10.1371/journal.pone.0002957 9. Burman W, Benator D, Vernon A, et al; Tuberculosis Trials Consortium. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J RespirCrit Care Med 2006; 173 (3) 350-356 10. Caminero JA, ed. Guidelines for Clinical and Operational Management of Drug-Resistant Tuberculosis. Paris, France: International Union against Tuberculosis and Lung Disease, 2013. 11. Caminero JA. Likelihood of generating MDR-TB and XDR-TB under adequate National Tuberculosis Control Programmeimplementation.lnt J Tuberc Lung Dis. 2008;12:869-77 12. Chang KC, Leung CC, Grosset J, Yew WVV. Treatment of tuberculosis and optimal dosing schedules. Thorax 2011; 66:997-1007. 13. Chang KC, Leung CC, Yew WW, Chan SL, Tam CM. Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis. Am J RespirCrit Care Med. 2006; 174:1153-8. 14. Cuevas LE, Al-SonboliN, Lawson L, et al. LED fluorescence microscopy for the diagnosis of pulmonary tuberculosis: a multi-country cross-sectional evaluation. PLoSMed. 2011;8:e1001057
U, oruma A.
15. Culqui DR, Munayco E CV, Grijalva CG, Cayla JA, Horna-Campos O, Alva Ch K, Suarez O LA. Factors associated with the non-completion of conventional anti-tuberculosis treatment in Peru. Arch Bronconeumol. 2012; 48: 150-5. 16. Culqui DR, Trujillo OV, Cueva N, Aylas R, Salaverry O, Bonilla C. Tuberculosis in the indigenous population of Peru 2008. Rey Peru Med ExpSaludPublica. 2010; 27:8-15. 17. Davis JL, Cattamanchi A, Cuevas LE, Hopewell PC, Steingart KR. Diagnostic accuracy of same-day microscopy versus standard microscopy for pulmonary tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2013; 13:147-54.
122